Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mei-Zi, Wang, Jie, Cao, Dong-Wei, Tu, Yue, Liu, Bu-Hui, Yuan, Can-Can, Li, Huan, Fang, Qi-Jun, Chen, Jia-Xin, Fu, Yan, Wan, Bing-Ying, Wan, Zi-Yue, Wan, Yi-Gang, Wu, Guo-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972405/
https://www.ncbi.nlm.nih.gov/pubmed/35370636
http://dx.doi.org/10.3389/fphar.2022.790937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972405/
https://www.ncbi.nlm.nih.gov/pubmed/35370636
http://dx.doi.org/10.3389/fphar.2022.790937

Ejemplares similares